{"name": "Genfit",
 "permalink": "genfit",
 "crunchbase_url": "http://www.crunchbase.com/company/genfit",
 "homepage_url": "http://www.genfit.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "+33 (0) 320 164 000",
 "description": "",
 "created_at": "Fri Mar 18 03:57:54 UTC 2011",
 "updated_at": "Fri Mar 18 03:58:27 UTC 2011",
 "overview": "\u003Cp\u003EGenfit SA, a biopharmaceutical company, engages in the research and development of drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases. The company focuses on various therapeutic areas, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer\u00e2\u20ac\u2122s diseases. Its lead proprietary program, GFT505, is an oral drug candidate under Phase II clinical trial for the treatment of pre-diabetes/diabetes. The company\u00e2\u20ac\u2122s products also include AVE0897 and SLV341, which are in Phase I clinical trial for the treatment of diabetes; SLV342, a pre-clinical product for the treatment of atherosclerosis; SAVX1, a pre-clinical products for the treatment of diabetes and vascular inflammation; BMGFT02, a pre-clinical product for the treatment of pre-diabetes/diabetes and beta-cell failure; and BMGFT01, a pre-clinical stage product for the treatment of Atherosclerosis. It has various collaboration, partnership, and strategic agreements with Sanofi-Aventis, Solvay group, Servier, and Merck. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       37],
      "assets/images/resized/0012/6768/126768v1-max-150x150.png"],
     [[218,
       55],
      "assets/images/resized/0012/6768/126768v1-max-250x250.png"],
     [[218,
       55],
      "assets/images/resized/0012/6768/126768v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman and CEO",
    "person":
     {"first_name": "Jean-Fran\u00c3\u00a7ois",
      "last_name": "Mouney",
      "permalink": "jean-franois-mouney",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Parc Eurasant\u00c3\u00a9",
    "address2": "885, Avenue Eug\u00c3\u00a8ne Avin\u00c3\u00a9e",
    "zip_code": "59120 ",
    "city": "Loos",
    "state_code": null,
    "country_code": "FRA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Genfit deal with sanofi-aventis worth up to $54.5M",
    "stoned_year": 2010,
    "stoned_month": 3,
    "stoned_day": 17,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily53-Genfit-deal-with-sanofi-aventis-worth-up-to-545M.html",
    "source_text": "",
    "source_description": "Genfit deal with sanofi-aventis worth up to $54.5M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Genfit",
      "permalink": "genfit"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}